Targeted Diseases

Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).

Non–alcoholic Steatohepatitis
More about NASH
Chronic Kidney Disease
More about CKD
Inflammatory Bowel Disease
More about IBD
Idiopathic Pulmonary Fibrosis
More about IBD